SLC2A2 and Insulin resistance: Our findings in this study revealed that cirsimaritin might be a very useful agent for the treatment of T2D due to its ability to reduce insulin resistance, and its activation of the GLUT4-AMPK and GLUT2-AMPK pathways in skeletal muscle, adipose tissue, and liver.